Traws Pharma, Inc. (NASDAQ:TRAW) Given Average Recommendation of “Reduce” by Analysts

Traws Pharma, Inc. (NASDAQ:TRAW) has been given a consensus rating of “Reduce” by the five ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $1.00.

Several brokerages have commented on TRAW. HC Wainwright restated a “negative” rating and issued a $1.00 price target on shares of Traws Pharma in a research note on Thursday, June 18th. Citigroup lowered Traws Pharma to a “neutral” rating in a report on Monday, June 15th. LADENBURG THALM/SH SH cut Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Weiss Ratings downgraded Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday, May 29th.

Traws Pharma Stock Performance

Traws Pharma stock opened at $0.53 on Tuesday. Traws Pharma has a one year low of $0.43 and a one year high of $3.27. The company has a 50-day simple moving average of $0.82 and a 200-day simple moving average of $1.44. The firm has a market capitalization of $8.06 million, a P/E ratio of -0.31 and a beta of 1.57.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.39. As a group, sell-side analysts forecast that Traws Pharma will post -1.43 earnings per share for the current year.

Institutional Investors Weigh In On Traws Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Investments LP lifted its holdings in Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares during the period. Geode Capital Management LLC increased its stake in Traws Pharma by 41.9% during the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after buying an additional 18,213 shares during the period. State Street Corp acquired a new position in Traws Pharma during the 4th quarter valued at about $29,000. Adage Capital Partners GP L.L.C. raised its position in shares of Traws Pharma by 121.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after buying an additional 400,000 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Traws Pharma during the 4th quarter worth about $175,000. 7.95% of the stock is currently owned by institutional investors.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.